Latest Personalised Medicine News

Tetratherix Limited launches a new precision medicine franchise leveraging its Tetramatrix™ platform, securing a decade-long exclusive partnership with US health group Superpower Health Inc. This deal promises immediate revenue and complements ongoing FDA milestones.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.

LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.

Rhythm Biosciences’ subsidiary Genetype has landed a pivotal 12-month contract with the University of Melbourne to provide advanced breast cancer risk assessments, marking a significant step in personalised cancer screening.

Vitura Health Limited has acquired Candor Medical, a leading Australian medicinal cannabis clinic, for $5.9 million, significantly boosting its digital health platform and patient base.